Combination of Raltitrexed and Oxaliplatin Is an Active Regimen in Malignant Mesothelioma: Results of a Phase II Study

Abstract

The raltitrexed and oxaliplatin combination is an active outpatient regimen in malignant mesothelioma and has an acceptable tolerability profile.

Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin–proteasome pathway as a therapeutic target in poor prognosis tumors

“…mRNA expression of UBE2D2 and PSMD8 was higher in biphasic 211H cells compared with H28 cells (Figure 3, lower panel), suggesting that these cells could model drug effects associated with ubiquitin-proteasome pathway gene expression. Oxaliplatin (l-OHP) is a third-generation platinum compound with activity in mesothelioma cell lines and in the clinical treatment of patients with malignant mesothelioma, where it is generally used in combination with other cytotoxic agents such as gemcitabine (Fizazi et al, 2003;Schutte et al, 2003). The clinical efficacy is limited by chemoresistance, which we hypothesized would be diminished by bortezomib.…”

“…The agents that produce response rates in 10-20% of patients include doxorubicin, detorubicin, epirubicin, carboplatin, mitomycin, cisplatin, cyclophosphamide and ifosfamide (Lee et al, 1996). More recently, combinations of gemcitabine/cisplatin (Nowak et al, 2002) and ralitrexed/oxaliplatin (Fizazi et al, 2003) for patients with pleural mesothelioma have shown objective response rates of up to 33%. A significant increment in chemotherapy effectiveness has been seen using pemetrexed in combination with carboplatin; a recent Phase III trial demonstrated a response rate of 42% and prolongation of median survival compared with cisplatin alone (Vogelzang et al, 2003).…”

Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy Improves Survival in Selected Patients with Peritoneal Carcinomatosis from Abdominal and Pelvic Malignancies: Results of 21 Cases

“…[1][2][3][4] The most widely accepted therapies for such PC are systemic chemotherapy, best support care, and palliative treatment, without any hope of cure. Moreover, surgery alone can only remove the bulky visible tumor burden.…”

Chemotherapy treatment in malignant pleural mesothelioma: a difficult history

“…The combination of cisplatingemcitabine (48), irinotecan-cisplatin-mitomycin (49), and oxaliplatin-raltitrexed (50,51), have also been evaluated as second-line approaches. Additionally, in the phase II trial by Giaccone et al, the platinum-complex ZD0473 showed no benefit as second-line strategy (52).…”